Table 3.
Patient and tumor characteristics by use of imaging-guide localization
| Variable | No IGL1, (N = 78) |
IGL1, (N = 422) |
p-Value2 |
|---|---|---|---|
| Country | < 0.001 | ||
| Austria | 1 (3.4%) | 28 (96.6%) | |
| Germany | 0 (0.0%) | 31 (100.0%) | |
| Hungary | 2 (2.0%) | 97 (98.0%) | |
| Italy | 0 (0.0%) | 2 (100.0%) | |
| Lithuania | 0 (0.0%) | 4 (100.0%) | |
| Switzerland | 75 (22.4%) | 260 (77.6%) | |
| Year | < 0.001 | ||
| 2018 | 0 (0.0%) | 20 (100.0%) | |
| 2019 | 29 (20.1%) | 115 (79.9%) | |
| 2020 | 18 (8.1%) | 204 (91.9%) | |
| 2021 | 9 (16.7%) | 45 (83.3%) | |
| 2022 | 22 (36.7%) | 38 (63.3%) | |
| Method of detection | 0.024 | ||
| Adjuvant, nonpalpable | 15 (9.2%) | 148 (90.8%) | |
| Adjuvant, palpable | 36 (20.9%) | 136 (79.1%) | |
| Neoadjuvant, nonpalpable | 14 (17.7%) | 65 (82.3%) | |
| Neoadjuvant, palpable | 13 (15.1%) | 73 (84.9%) | |
| Clinical T stage at initial diagnosis | 0.10 | ||
| cT0 | 1 (50.0%) | 1 (50.0%) | |
| cT1 | 24 (20.5%) | 93 (79.5%) | |
| cT2 | 35 (12.0%) | 257 (88.0%) | |
| cT3 | 12 (20.3%) | 47 (79.7%) | |
| cT4 | 5 (20.8%) | 19 (79.2%) | |
| cTis (DCIS) | 0 (0.0%) | 1 (100.0%) | |
| cTx | 1 (20.0%) | 4 (80.0%) | |
| Postoperative N stage | 0.4 | ||
| pN1 | 28 (13.6%) | 178 (86.4%) | |
| pN2 | 17 (20.0%) | 68 (80.0%) | |
| pN3 | 6 (14.0%) | 37 (86.0%) | |
| Unknown | 0 (0.0%) | 2 (100.0%) | |
| ypN0 | 1 (100.0%) | 0 (0.0%) | |
| ypN0(ITC) | 0 (0.0%) | 4 (100.0%) | |
| ypN1 | 21 (17.2%) | 101 (82.8%) | |
| ypN2 | 5 (17.9%) | 23 (82.1%) | |
| ypN3 | 0 (0.0%) | 9 (100.0%) | |
| Tumor type | 0.5 | ||
| NST | 59 (15.2%) | 330 (84.8%) | |
| Invasive lobular | 8 (13.3%) | 52 (86.7%) | |
| Other | 11 (22.0%) | 39 (78.0%) | |
| Unknown | 0 (0.0%) | 1 (100.0%) | |
| Tumor grade | 0.093 | ||
| G1 | 2 (6.2%) | 30 (93.8%) | |
| G2 | 41 (13.9%) | 253 (86.1%) | |
| G3 | 35 (20.7%) | 134 (79.3%) | |
| Unknown | 0 (0.0%) | 5 (100.0%) | |
| Tumor receptor subtype | 0.003 | ||
| HR+/HER2− | 57 (14.4%) | 340 (85.6%) | |
| HR+/HER2+ | 6 (11.5%) | 46 (88.5%) | |
| HR−/HER2+ | 2 (40.0%) | 3 (60.0%) | |
| HR−/HER2− | 13 (37.1%) | 22 (62.9%) | |
| Unknown | 0 (0.0%) | 11 (100.0%) |
1n (%), percentages calculated row-wise
2Fisher’s exact test
IGL imaging-guided localization, DCIS ductal carcinoma in situ, ITC isolated tumor cells, HR hormone receptor, HER2 human epidermal growth factor receptor 2